We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
VBI Vaccines Inc is a biotechnology business with stocks listed in the US. VBI Vaccines shares (VBIV) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$2.86 – a decrease of 5.3% over the previous week. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | US$2.44 - US$4.83 |
|---|---|
| 50-day moving average | US$3.0842 |
| 200-day moving average | US$3.2184 |
| Target price | US$8 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | US$-0.264 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $2.86
| 1 week (2021-11-18) | -5.30% |
|---|---|
| 1 month (2021-10-26) | -3.05% |
| 3 months (2021-08-26) | -15.63% |
| 6 months (2021-05-26) | -11.18% |
| 1 year (2020-11-25) | 5.15% |
|---|---|
| 2 years (2019-11-25) | 318.37% |
| 3 years (2018-11-23) | 63.43% |
| 5 years (2016-11-25) | -5.30% |
| Revenue TTM | US$714,000 |
|---|---|
| Gross profit TTM | US$-8,107,000 |
| Return on assets TTM | -18.1% |
| Return on equity TTM | -40.7% |
| Profit margin | 0% |
| Book value | 0.622 |
| Market capitalisation | US$766.8 million |
TTM: trailing 12 months
We're not expecting VBI Vaccines to pay a dividend over the next 12 months.
VBI Vaccines's shares were split on a 1:40 basis on 1 May 2016. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VBI Vaccines shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for VBI Vaccines shares which in turn could have impacted VBI Vaccines's share price.
Over the last 12 months, VBI Vaccines's shares have ranged in value from as little as US$2.44 up to US$4.83. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VBI Vaccines's is 1.9268. This would suggest that VBI Vaccines's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. The company primarily serves physicians and pharmacists through direct sales. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition For Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.
Amazon's best Black Friday deals include 50% off video games, 40% on Samsung Galaxy smartphones, 70% off Kindle books.
If you’re a content creator or vlogger, the Sony Alpha ZV-E10 could be the mirrorless, interchangeable lens camera you have been looking for.
For the first time in a decade Australia has a rising inflation rate. We discuss what it means for households, wages and how investors should react to higher inflation.
Amazon has knocked 34% off PlayStation Plus 12 Month Membership cards as part of its mid-year sale - save $27.95!
2021's best early-bird Black Friday fashion deals include 60% off at JD Sports, 80% off at White Fox Boutique and 50% off at THE ICONIC
Bank CEOs must hate me because I save so much money on my mortgage. Here's how I do it.
Ethereum continues to struggle as the currency’s weekly losses now stand at 13.3%.
There are over 500,000 seats on sale and for the first time in 2 years, fly to 22 international destinations.
